Market Outlook

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibitors have transformed the management of advanced NSCLC. In late 2018, Tecentriq (Roche/Genentech/Chugai) was the second immune checkpoint inhibitor to enter the coveted first-line metastatic setting, after Keytruda (Merck & Co.). Competition is set to intensify further over the forecast period as multiple combination therapies based on immune checkpoint inhibitors gain approval and enter the clinic. In addition, novel biomarker-driven therapies such as next-generation EGFR and ALK inhibitors are vying for a share of the increasingly crowded and competitive NSCLC market.

Questions Answered

  •  How large are the drug-treatable NSCLC populations and how will drug-treatment rates change over time in market-relevant populations?
  • How will recent and expected market approvals shape uptake of immune checkpoint inhibitors in first-line metastatic NSCLC? Which agents and combinations will dominate this commercially lucrative disease setting?
  • What pipeline products are most promising, and what uptake and sales could they secure in NSCLC? What therapies of note are progressing in earlier phases of development?
  • What are the key market drivers and constraints in NSCLC, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • September 2019
      • May 2019
      • December 2018
      • October 2018
      • September 2018
    • Market Outlook
      • Market Outlook
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for NSCLC?
        • What Factors Are Constraining the Market for NSCLC?
      • Segment-Specific Trends
        • Stage IB-II NSCLC
        • Stage III NSCLC
        • First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer
        • Second- and Third-Line Treatment of Metastatic Non-Small-Cell Lung Cancer
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Expert Insight
        • Disease Overview
        • Pathophysiology
        • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution at Diagnosis
        • Recurrent Incident Cases
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • EGFR Inhibitors
        • ALK Inhibitors
        • Immune Checkpoint Inhibitors
        • BRAF/MEK Inhibitors
        • Angiogenesis Inhibitors
        • Cytotoxic Agents
      • Medical Practice
        • Region-Specific Treatment Practices
    • Unmet Need
      • Introduction
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Non-Small-Cell Lung Cancer
        • Future Attainment of Unmet Needs
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • ALK Inhibitors
        • ROS1 Inhibitors
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • Poly ADP-Ribose Polymerase Inhibitors
        • Therapeutic Vaccines
        • Cytokine Targeted Therapies
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for NSCLC
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • U.S. Reimbursement Dynamics
        • Reimbursement Dynamics in Biomarker Targeted Metastatic NSCLC in the United States: Current and Future
      • EU5 Reimbursement Dynamics
        • Payer Insight on Future Reimbursement of Biomarker-Targeted Therapies for NSCLC
      • EU5 Access & Reimbursement Considerations for Emerging Therapies
        • Access & Reimbursement Considerations for Emerging Biomarker-Targeted NSCLC Therapies in the EU5
        • Payer Insight on Emerging Biomarker-Targeted NSCLC Therapies
      • China Reimbursement Dynamics: Current & Future
      • China Access & Reimbursement Considerations for Emerging Therapies
        • Payer Insight on Emerging Therapies for CRC
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • NSCLC Bibliography

Author(s): Joshua Dawkins, M.Pharmacol., PhD; Lade Ayodele

Joshua Dawkins, , is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.

Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets. Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.

Related Reports

Non-Small-Cell Lung Cancer | Geographic Focus: China | Non-Small-Cell Lung Cancer | China In-Depth | China

MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of...

View Details

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...

View Details

Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2018

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies i...

View Details

Non-Small-Cell Lung Cancer | Current Treatment | Detailed, Expanded Analysis Physician Insights (US)

MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The

View Details